Refine
Has Fulltext
- yes (22)
Is part of the Bibliography
- yes (22)
Year of publication
Document Type
- Doctoral Thesis (22)
Keywords
- Maus (5)
- Serotonin (5)
- ADHD (4)
- ADHS (4)
- Aufmerksamkeitsdefizit-Syndrom (3)
- Cadherine (3)
- Depression (3)
- Epigenetik (3)
- Genetics (3)
- Genexpression (3)
Institute
- Graduate School of Life Sciences (16)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (5)
- Lehrstuhl für Molekulare Psychiatrie (4)
- Medizinische Fakultät (2)
- Fakultät für Biologie (1)
- Institut für Humangenetik (1)
- Medizinische Klinik und Poliklinik I (1)
- Neurologische Klinik und Poliklinik (1)
- Theodor-Boveri-Institut für Biowissenschaften (1)
Sonstige beteiligte Institutionen
ResearcherID
- N-8985-2015 (1)
The research that is compiled in this thesis can be divided in two parts. The first part, consisting of four chapters, is centered around the role of epigenetic dysregulation in the etiopathophysiology of sporadic alzheimer's disease (sAD). In addition to providing insights into the most recent developments in neuroepigenomic studies of this disease, the first part of the thesis also touches upon remaining challenges, and provides a future outlook on possible developments in the field. The second part, which includes three more chapters, is focused on the application of induced pluripotent stem cell (iPSC)-based disease models for the study of AD, including but not limited to mechanistic studies on epigenetic dysregulation using this platform. Aside from outlining the research that has been conducted using iPSC-based models for sAD to date, the second part of the thesis also provides insights into the acquisition of disease-relevant neural cultures based on directed differentiation of iPSCs, and furthermore includes an experimental approach for the establishment of such a model system.
While the healthy brain works through balanced synaptic communication between
glutamatergic and GABAergic neurons to coordinate excitation (E) and inhibition (I), disruption
of E/I balance interferes with synaptic communication, information processing, and ultimately
cognition. Multiple line of evidence indicates that E/I imbalance represents the
pathophysiological basis of a wide spectrum of mental disorders. Genetic screening
approaches have identified Cadherin-13 (CDH13). as a risk gene across neurodevelopmental
and mental disorders. CDH13 regulates several cellular and synaptic processes in brain
development and neuronal plasticity in adulthood. In addition to other functions, it is specifically
localized at inhibitory synapses of parvalbumin- and somatostatin-expressing GABAergic
neurons. In support of CDH13’s function in moderating E/I balance, electrophysiological
recordings of hippocampal slices in a CDH13-deficient mouse model revealed an increase in
basal inhibitory but not excitatory synaptic transmission. Moreover, the search for genetic
variants impacting functional expression of the CDH13 gene identified SNP (single nucleotide
polymorphism)) rs2199430 in intron 1 to be associated with differential mRNA concentrations
in human post-mortem brain across the three genotypes CDH13G/G, CDH13A/G and CDH13A/A
.
This work therefore aimed to further validate these findings in a complementary human model
by using induced pluripotent stem cells (iPSCs). The application of human iPSCs in research
has replaced the use of embryonic cells, resolving the ethical conflict of destructive usage of
human embryos. Investigating CDH13’s mode of action in inhibitory synapses was predicted
to facilitate mechanistic insight into the effects of CDH13 gene variants on E/I network activity,
which can then be targeted to reinstate balance.
Genome-wide association studies have identified rare copy number variants (CNVs) resulting
in a deletion (or duplication) of CDH13. To reduce genetic background variance, a set of
isogenic iPSC lines with a gene dose-dependent deficiency of CDH13 (CDH13-/- and CDH13+/-
) was generated by using the Clustered Regulatory Interspaced Short Palindromic
Repeats/CRISPR-associated protein 9 (CRISPR/Cas9) system. These CRISPRed iPSCs
carrying a single or two allele(s) with CDH13 inactivation facilitate investigation of CDH13
function in cellular processes, at inhibitory synapses and in neuronal network activity. In
addition, iPSCs carrying allelic SNP rs2199430 variants were used to study the effects of
common genetic variation of CDH13. These cell lines were differentiated into pure
glutamatergic and GABAergic neurons and co-cultured to generate neuronal networks allowing
its activity to be measured and correlated with electrophysiological signatures of differential
CDH13 genotypes. The work towards assessment of neuronal network activity of the iPSC
lines was subdivided into three major steps: first, generating rtTA/Ngn2 and rtTA/Ascl1-positive
iPSCs via a lentivirus-mediated approach; second, differentiating pure glutamatergic and
GABAergic neurons from the genetically transduced iPSCs and co-culturing of pure
glutamatergic and GABAergic neurons in a pre-established ratio (65:35) by direct
differentiation upon supplementation with doxycycline and forskolin on a microelectrode array
(MEA) chip; and, finally, recording of neuronal network activity of iPSC lines after 49 days in
vitro, followed by extraction and analyses of multiple MEA parameters.
x
Based on the MEA parameters, it was confirmed that complete CDH13 knockout as well as
heterozygous deficiency influence E/I balance by increasing inhibition. It was further revealed
that common SNP variation alters the signature of neuronal network activity. Specifically,
CDH13 deficiency resulted in a significant reduction in network burst duration (NBD), reduced
number of detected spikes within a network burst and reduction in network burst rate (NBR)
compared to the control (CDH13G/G). CDH13A/G and CDH13A/A showed similarities with the
CRISPRed CDH13-deficient networks by showing a significant reduction in the NBD and a
reduced number of detected spikes within a network compared to CDH13G/G. Strikingly. there
was a significant increase in the NBR of the CDH13A/G and CDH13A/A compared to CDH13G/G
networks. CDH13A/G networks exhibited significant differences in both parameters. At the
cellular level, this indicates that signalling pathways which determine the length and frequency
of network bursts differ among allelic variants of SNP rs2199430, thus confirming functional
relevance of this intronic SNP.
In summary, CDH13-deficient isogenic iPSC lines were generated using CRISPR/Cas9, iPSCs
were genetically transduced via a lentivirus approach, direct differentiation of
glutamatergic/GABAergic neurons derived from transduced iPSCs were used to establish a
scalable co-culture system, and network activity was recorded by MEA using pre-established
parameters to extract and analyze activity information. The results indicate that iPSC-derived
neuronal networks following CRISPR/Cas9-facilitated CDH13 inactivation, as well as networks
with allelic SNP variants of CDH13, moderate E/I balance, thus advancing understanding of
CDH13 function at inhibitory synapses and elucidating the effects of rare and common CDH13
gene variation.
Cadherin-13 (CDH13) is a member of the cadherin superfamily that lacks the typical transmembrane domain for classical cadherins and is instead attached to the cell membrane with a GPI-anchor. Over the years, numerous genome-wide association (GWA) studies have identified CDH13 as a risk factor for neurodevelopmental disorders, including attention- deficit/hyperactivity disorder (ADHD) and autism spectrum disorder. Further evidence using cultured cells and animal models has shown that CDH13 plays important roles in cell migration, neurite outgrowth and synaptic function of the central nervous system. Research in our laboratory demonstrated that the CDH13 deficiency resulted in increased cell density of serotonergic neurons of the dorsal raphe (DR) in developing and mature mouse brains as well as serotonergic hyperinnervation in the developing prefrontal cortex, one of the target areas of DR serotonergic neurons. In this study, the role of CDH13 was further explored using constitutive and serotonergic system-specific CDH13-deficient mouse models. Within the adult DR structure, the increased density of DR serotonergic neurons was found to be topographically restricted to the ventral and lateral-wing, but not dorsal, clusters of DR. Furthermore, serotonergic hyperinnervation was observed in the target region of DR serotonergic projection neurons in the lateral wings. Unexpectedly, these alterations were not observed in postnatal day 14 brains of CDH13-deficient mice. Additionally, behavioral assessments revealed cognitive deficits in terms of compromised learning and memory ability as well as impulsive-like behaviors in CDH13-deficient mice, indicating that the absence of CDH13 in the serotonergic system alone was sufficient to impact cognitive functions and behavioral competency. Lastly, in order to examine the organization of serotonergic circuitries systematically and to tackle limitations of conventional immunofluorescence, a pipeline of the whole-mount immunostaining in combination with the iDISCO+ based rapid tissue clearing techniques was established. This will facilitate future research of brain neurotransmitter systems at circuitry and/or whole-brain levels and provide an excellent alternative for visualizing detailed and comprehensive information about a biological system in its original space. In summary, this study provided new evidence of CDH13’s contribution to proper brain development and cognitive function in mice, thereby offering insights into further advancement of therapeutic approaches for neurodevelopmental disorders.
Zusammenfassung
1) Fragestellung und zentrale Untersuchung
Unter der Hypothese, dass die Transportrate des Glukosetransporters Typ 3 (GLUT3)
abhängig von der Kopienanzahl (CNV) des für ihn kodierenden Gens SLC2A3 ist,
wurden Zelllinien mit drei Kopien (Duplikation) mit Kontroll-Zelllinien mit nur zwei Kopien
bezüglich ihrer Glukoseaufnahme miteinander verglichen (n=2; N=9). Hierzu wurde die
zelluläre Glukoseaufnahme mittels radioaktiv markierter 2-Desoxyglukose in via
Eppstein-Barr-Virus immortalisierten lymphoblastoiden Zelllinien (EBV-LCLs)
gemessen. In den initialen Untersuchungen zeigt sich, dass das Protokoll an manchen
Stellen zu viel Spielraum lässt. Die Methode wird daraufhin standardisiert und bezüglich
einiger Parameter angepasst: g-Zentrifugeneinstellung, Mischen/Aliquotieren,
Zellanzahl, Replikatanzahl, Inkubationszeit/-intervalle und Durchführungsdauer.
2) Wichtigste Ergebnisse
Die funktionelle Untersuchung zur Duplikation des SLC2A3-Gens in Patienten mit
Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) zeigt schließlich im
dynamischen Aushungerungsversuch der EBV-LCLs über vier Tage (Vergleich t2 zu t1)
statistisch für die Gruppen eine deutliche Differenz mit mittlerer Effektstärke (Lineares
Gemischtes Modell; p = 0,06; Cohens d = 0,37).
Zum zweiten Messzeitpunkt (t2) zeigt sich statistisch zwischen den Gruppen eine sehr
signifikante Differenz mit hoher Effektstärke (Lineares Gemischtes Modell; p < 0,006;
Cohens d = 0,55).
Damit konnte in dieser Arbeit nachgewiesen werden, dass die SLC2A3-Duplikation
neben dem Gendosiseffekt auf mRNA-Ebene auch hypermorph funktionelle
Veränderungen auf zellulärer Ebene nach sich zieht. Nachfolgende Untersuchungen
sollten vor diesem Hintergrund mögliche Kofaktoren investigieren und auf Alterationen
in nachgeschalteten Signalwegen abzielen.
Neuropsychiatric disorders, such as attention-deficit/hyperactivity disorder (ADHD), represent a burden which deeply impair the patient’s life. Neurobiological research has therefore increasingly focused on the examination of brain neurotransmitter systems, such as the serotonin (5-HT) system, since a dysfunction has been repeatedly implicated in the pathology of these diseases. However, investigation of functional human neurons in vitro has been restricted by technical limitations for a long time until the discovery of human induced pluripotent stem cells (iPSCs) revolutionized the field of experimental disease models. Since the pathogenesis of neuropsychiatric disorders involves a complex genetic component, genome-wide association studies (GWAS) revealed numerous risk genes that are associated with an increased risk for ADHD. For instance, the novel ADHD candidate gene SLC2A3 which encodes the glucose transporter-3 (GLUT3), facilitates the transport of glucose across plasma membranes and is essential for the high energy demand of several cell types, such as stem cells and neurons. Specifically, copy number variants (CNVs) of SLC2A3 might therefore impact cerebral glucose metabolism as well as the assembly of synaptic proteins in human neurons which might contribute to the pathogenesis of ADHD.
We hypothesized that an altered SLC2A3 gene dosage in human neurons can exert diverse protective or detrimental effects on neurodevelopmental processes as well as the coping of glucometabolic stress events, such as hypo- and hyperglycaemic conditions. The generation of specific iPSC lines from ADHD patients and healthy probands served as basis to efficiently differentiate stem cells into 5-HT specific neurons. Using this neuronal culture, we were able to examine effects of SLC2A3 CNVs on the basal expression of SCL2A3 and GLUT3 in human neurons. Furthermore, the focus was on potentially altered coping of the cells with glucose deprivation and the treatment with specific high- and low glycaemic media.
High-resolution fluorescence imaging in combination with electrophysiological and molecular biological techniques showed that:
1) The generated human iPSCs are fully reprogrammed human stem cells showing typical characteristics of embryonic stem cell-like morphology, growth behaviour, the ability to differentiate into different cell types of the human body and the expression of pluripotency-specific markers.
2) The neuronal subtype derived from our stem cells display typical characteristics of 5-HT specific median and dorsal neurons and forms synapses reflected by the expression of pre- and postsynaptic proteins.
3) Even if SLC2A3 CNVs influence SLC2A3 and GLUT3 basal expression, no significant alterations in gene and protein expression caused by hyper- and hypoglycaemic conditions, nor in the assembly of proteins associated with synapse formation could be observed in human iPSC-derived neurons.
Angsterkrankungen gehören zu den am weitesten verbreiteten psychischen Erkrankungen und stellen eine beträchtliche soziale und wirtschaftliche Herausforderung für unsere Gesellschaft dar. Aversive frühe Erfahrungen sind ein bekannter Risikofaktor für die Entwicklung verschiedener psychischer Erkrankungen, insbesondere Angststörungen. Während der frühen Entwicklung findet die Programmierung der Hypothalamus-Hypophysen-Nebennierenrinden- (HHN)-Achse, die die Ausschüttung des Stresshormons Cortisol in Menschen bzw. Corticosteron in Mäusen steuert, statt. Wenn Individuen in dieser kritischen Phase Stress ausgesetzt sind, wird die regelrechte Ausbildung der HHN-Achse gestört, was zu dysregulierten Verhaltensantworten auf Stressreize im späteren Leben führen kann. Das Serotonin (5-HT)-System als eines der ausgedehntesten Neurotransmittersysteme ist an der Vermittlung der Effekte von früher Stressexposition auf angstähnliche Verhaltensweisen beteiligt.
Das Ziel dieser Studie ist es, die Interaktion zwischen genetischer Prädisposition und negativen Einflüssen in frühen Entwicklungsstadien auf die Ausbildung von Angstverhalten im Erwachsenenalter näher zu beleuchten.
In dieser Studie wurden Tryptophanhydroxylase 2 (Tph2)-defiziente weibliche Mäuse als Modell für ein lebenslanges konstitutives 5-HT Synthesedefizit im zentralen Nervensystem verwendet. Nachkommen dieser Mauslinie wurden im frühen Lebensalter Maternaler Separation (MS), d.h. einem mütterlichen Trennungsparadigma, unterzogen und im Erwachsenenalter im „Open field“ (OF) oder in der „Dark-light box“ (DLB) getestet. Im Anschluss an die Verhaltensexperimente wurde die neuronale Aktivierung immunhistochemisch durch Darstellung des frühzeitig auftretenden Genprodukts c-Fos bestimmt.
In der DLB zeigten homozygot Tph2-defiziente Mäuse eine verringerte motorische Aktivität im hellen Kompartiment, und dieser Effekt konnte durch MS normalisiert werden. Zusätzlich verstärkte MS bei diesem Genotyp das Auftreten von fluchtartigen Sprüngen. Im OF hat MS fluchtartige Verhaltensweisen in homo- und heterozygoten Tph2-defizienten Mäusen befördert.
Beide Verhaltenstests führten zu spezifischen neuronalen Aktivierungsmustern, die mithilfe von c-Fos- Immunhistochemie ausgewertet wurden. Die Durchführung des DLB-Tests führte in Abhängigkeit vom Vorhandensein von Tph2 zur Aktivierung des paraventrikulären Kerns des Hypothalamus (PVN) und der basolateralen Amygdala (BL), wohingegen die Exposition gegenüber dem OF-Test zu einer Aktivierung der lateralen Amygdala (La) in Tieren, die einem mütterlichen Trennungsparadigma unterzogen wurden, sowie einer Aktivierung des ventrolateralen (VLPAG) und dorsolateralen (DLPAG) periaquäduktalen Höhlengraus in Abhängigkeit von Tph2 und MS führte.
Zusammenfassend weisen die Ergebnisse dieser Studie darauf hin, dass MS aktive Verhaltensantworten auf aversive Reize in Abhängigkeit vom Vorhandensein von 5-HT im Gehirn fördert. Diese Effekte könnten durch die spezifische Aktivierung von mit Angstverhalten in Zusammenhang stehenden Gehirnregionen während der Verhaltensexperimente vermittelt werden.
Angesichts des dramatischen, weltweiten Anstiegs der Prävalenz von Demenzerkrankungen und der aktuellen, unzureichenden Therapieansätze ist die Bereitstellung neuer, wirkungsvoller Behandlungsoptionen von größter Bedeutung. Technologische, pharmakologische und verhaltensbasierte Verfahren des Memory Enhancement könnten zur Lösung dieses Problems beitragen: Hierzu zählt die Stammzelltransplantation, die in mehreren Tierstudien zu einer Verbesserung der Gedächtnisfunktion führte. Zudem wird seit Längerem an einer Impfung gegen die Alzheimer-Krankheit mittels β-Amyloid-Antikörpern geforscht. Ein weiterer therapeutischer Ansatz für die Alzheimer-Krankheit besteht in der optogenetischen Stimulation spezifischer hippocampaler Engramm-Zellen, durch die bei einem Maus-Modell verloren gegangene Erinnerungen wiederhergestellt werden konnten. Unkonventionelle Pharmazeutika wie Erythropoetin führten in Tierstudien und bei Patienten mit neuropsychiatrischen Erkrankungen zu einer Verbesserung der kognitiven Fähigkeiten und des Gedächtnisses. Eine Modifikation der Ernährung und der Einsatz von Pro- und Präbiotika beeinflussen das Gedächtnis über eine Manipulation der Darm-Hirn-Achse. Verhaltensbasierte Maßnahmen wie körperliche Aktivität und der Einsatz von Mnemotechniken stellen effektive Ansätze des Memory Enhancement dar, welche bereits heute von gesunden Individuen implementiert werden können. Für die Anwendung von Augmented Reality (AR) konnten kognitionsfördernde Wirkungen beim Lernen neuroanatomischer Themen und dem Zusammenbau von Objekten nachgewiesen werden. Besonders vielversprechend stellt sich die Entwicklung einer Gedächtnisprothese dar, durch die vergessene Informationen bei Personen mit stattgehabtem Schädel-Hirn-Trauma und apoplektischem Insult reaktiviert werden könnten. Memory Enhancement ist prinzipiell bereits heute bei gesunden und kranken Individuen anwendbar und verspricht wirksame zukünftige Präventions- und Therapieoptionen. Ein realer Einsatz in der klinischen Praxis ist in naher Zukunft jedoch noch nicht zu erwarten.
Serotonin (5-hydroxytryptamine, 5-HT) is a neurotransmitter involved in early
developmental processes such as cell proliferation, migration, and differentiation.
Recent research in humans showed that the brain 5-HT system and CDH13 are
interlinked in the genetics of neurodevelopmental disorders including attention-
deficit/hyperactivity disorder and autism spectrum disorder (Lesch et al., 2008;
Neale et al., 2008; Neale, Medland, Ripke, Anney, et al., 2010; Neale, Medland,
Ripke, Asherson, et al., 2010; Sanders et al., 2011; Sanders et al., 2015; Zhou et
al., 2008). This study introduces Cadherin-13 (CDH13), a cell adhesion protein, as
a contributor to the development and function of the 5-HT system. Our
experiments show that the absence of CDH13 increases the density of 5-HT
neurons in the developing dorsal raphe (DR) and increases the 5-HT innervation
of the prefrontal cortex in mouse embryonic stages. CDH13 is also observed in
radial glial cells, an important progenitor cell type linked to neuronal migration.
A three-dimensional reconstruction carried out with super-resolution microscopy,
identifies 5-HT neurons intertwined with radial glial cells, and CDH13 clusters at
contact points between these cells. This indicates a potential contribution of
CDH13 to the migration of DR 5-HT neurons. As CDH13 is strongly expressed in
5-HT neurons, we asked whether the selective deletion of CDH13 from these cells
is sufficient to generate the alterations observed in the Cdh13 constitutive
knockout mouse line.
In 5-HT conditional Cdh13 knockout mice (Cdh13 cKO) an increase in DR 5-HT
neurons in the embryonic and adult brains is observed, as well as 5-HT
hyperinnervation of cortical regions. Therefore, illustrating that the lack of CDH13
from 5-HT neurons alone impacts DR formation and serotonergic innervation.
Behavioral testing conducted on Cdh13 cKO mice showed delayed learning in
visuospatial learning and memory processing, as well as, changes in sociability
parameters. To find out how CDH13 localizes in human 5-HT neurons, CDH13 was
visualized in neurons that derived from human induced pluripotent stem cells
(iPSC). Super-resolution microscopy confirmed CDH13 expression in a subgroup
of induced human neurons positive for typical hallmarks of 5-HT neurons, such as
expression of Tph2, the neuron-specific tryptophan hydroxylase, and synaptic
structures. In summary, the work included in this thesis presents a detailed
analysis of CDH13 expression and localization in the 5-HT system and shows that
deletion of CDH13 from 5-HT neurons affects specific higher-order functions of the
brain.
This thesis explores the development of monoaminergic systems in the central nervous system (CNS) of zebrafish. The serotonergic cells of the hypothalamus pose the main focus of the present work. Most vertebrates except for mammals possess serotonin (5-HT) synthesising cells in more than one region of the CNS. In zebrafish such regions are, e.g. the hypothalamus, the raphe nuclei and the spinal cord. Serotonin functions as a neurotransmitter and neuromodulator in the CNS. Presumably due to its neuromodulatory tasks hypothalamic serotonergic cells are in contact with the cerebrospinal fluid (CSF), which expands the field of potential serotonergic targets tremendously. This highlights that serotonergic CSF-contacting (CSF-c) cells are vital for the execution of many functions and behaviours. Further, the hypothalamic serotonergic clusters constitute the largest population of serotonergic cells in the CNS of zebrafish. Together, these facts emphasise the need to understand the development and function of serotonergic CSF-c cells in the hypothalamus. Few studies have dealt with this subject, hence, information about the development of these cells is scarce. The zinc-finger transcription factor fezf2, and Fibroblast growth factor (Fgf)-signalling via the ETS-domain transcription factor etv5b are known to regulate serotonergic cell development in the hypothalamus (Bosco et al., 2013; Rink and Guo, 2004). However, the main Fgf ligand responsible for this mediation has not been determined prior to this work. The present thesis identifies Fgf3 as a crucial Fgf ligand. To achieve this result three independent strategies to impair Fgf3 activity have been applied to zebrafish embryos: the fgf3t24152 mutant, an fgf3 morpholino-based knock-down and the CRISPR/Cas9 technique. The investigations show that Fgf3 regulates the development of monoaminergic CSF-c cells in the hypothalamus. Additionally, Fgf3 impacts on cells expressing the peptide hormone arginine vasopressin (avp). Most interestingly, the requirement for Fgf3 by these cells follows a caudo-rostral gradient with a higher dependence on Fgf3 by caudal cells. This also seems to be the case for dopaminergic CSF-c cells in the hypothalamus (Koch et al., 2014). Moreover, etv5b a downstream target of Fgf-signalling is demonstrated to be under the control of Fgf3. With regard to serotonergic CSF-c cell development, it is shown that fgf3 is expressed several hours before tph1a and 5-HT (Bellipanni et al., 2002; Bosco et al., 2013). Together with the result that the hypothalamus is already smaller before mature serotonergic CSF-c cells appear, this argues for an early impact of Fgf3 on serotonergic specification. This hypothesis is supported by several findings in this study: the universal decrease of proliferating cells in the hypothalamus and simultaneous increase of cell death after fgf3 impairment. Complementary cell fate experiments confirm that proliferating serotonergic progenitors need Fgf3 to commit serotonergic specification. Further, these results corroborate findings of an earlier study stating that hypothalamic serotonergic progenitors require Fgf-signalling via etv5b to maintain the progenitor pool (Bosco et al., 2013). Additionally, the transcriptome of the hypothalamus has been analysed and 13 previously overlooked transcripts of Fgf ligands are expressed at developmental stages. The transcriptome analysis provides evidence for a self-compensatory mechanism of fgf3 since expression of fgf3 is upregulated as a consequence of its own impairment. Moreover, the Fgf-signalling pathway appears to be mildly affected by fgf3 manipulation. Together, Fgf-signalling and especially Fgf3 are established to be of critical importance during hypothalamic development with effects on serotonergic, dopaminergic CSF-c and avp expressing cells. Furthermore, this thesis provides two strategies to impair the tph1a gene. Both strategies will facilitate investigations regarding the function of hypothalamic serotonergic CSF-c cells. Finally, the presented findings in this study provide insights into the emergence of the posterior recess region of the hypothalamus, thereby, contributing to the understanding of the evolution of the vertebrate hypothalamus.
Natrium-Glukose Transporter (SGLT) gehören zur „solute carrier 5“ (SLC5) Familie, die sich durch einen sekundär aktiven, natriumabhängigen Transport von Zuckern und an-deren Molekülen nach intrazellulär auszeichnen. Die durch das Gen SLC5A4 kodierte Isoform SGLT3 transportiert dagegen keinen Zucker, sondern verhält sich als Glukosesensor, der nach Bindung seiner Liganden eine Membrandepolarisation induziert. In genomweiten Exomsequenzierungsstudien (whole exome sequencing, WES) mehrerer erweiterter Stammbäume mit hoher Prävalenz des Aufmerksamkeitsdefizit-/Hyperaktivitätssyndroms (ADHS) wurde im Vorfeld eine ATG-Tripletdeletion in SLC5A4 identifiziert, die zum Verlust einer Aminosäure (ΔM500) in SGLT3 führt und zumindest partiell mit dem klinischen Phänotyp kosegregiert.
In der vorliegenden Arbeit wurde die zentralnervöse Expression von SGLT3 auf RNA- Ebene mittels Reverse-Transkriptase PCR sowie real-time PCR aus humanen Gesamt-RNAs nachgewiesen. Dabei konnte eine ubiquitäre Expression im Gehirn mit relativ erhöhter Expression unter anderem in Striatum und Hypothalamus, deren Dysfunktion in der Pathogenese des ADHS impliziert wurde, gezeigt werden. Da Mutationen in homologen Domänen der eng strukturverwandten Isoformen SGLT1 und SGLT2 sowohl intestinale als auch renale Funktionen schwer beeinträchtigen, wurden in dieser Arbeit funktionelle Charakteristika sowohl des wildtypischen als auch der ΔM500 und der benachbarten ΔI501 Deletionsvariante von SGLT3 mittels Zwei-Elektroden Spannungs- und Stromklemme in entsprechend cRNA-injizierten Xenopus laevis Oozyten untersucht. Der hochpotente SGLT3-spezifische Iminozuckeragonist 1-Desoxynojirimycin (DNJ) induzierte an SGLT3-exprimierenden Oozyten in sauren Bedingungen etwa dreifach größere Kationeneinströme als D-Glukose, was sowohl im Spannungsklemmen-, und anhand einer entsprechenden Membrandepolarisation im Stromklemmenmodus gezeigt wurde. Die mit der ΔM500 bzw. ΔI501 Variante injizierten Oozyten dagegen zeigten in den maximalen Aktivierungsbedingungen um 92% bzw. 96% (p<0,01) reduzierte Kationeneinströme, sodass diese als hochgradig schädliche „Loss of Function“ Mutationen in SGLT3 charakterisiert wurden. Dieser Befund wurde mittels bioinformatischer in-silico Effektvorhersage validiert.
Um Konsequenzen der Sequenzalteration auf den Membraneinbau der Transporter zu untersuchen, wurden die mit einem gelb fluoreszierenden Farbstoff (YFP) markierten Transporter in Oozytenmembranen mittels Laser-Scanning Mikroskop nachgewiesen und die jeweiligen Mengen der Konstrukte anhand der Fluoreszenzintensitäten quantifiziert. Dabei zeigte sich eine um 53% bzw. 42% (p<0,01) reduzierte Menge der mutierten Konstrukte ΔM500 bzw. ΔI501 in der Membran, was zusätzliche schädliche Effekte der Mutationen auf das sogenannte Membrantargeting der Transporter belegt.
Zusammenfassend demonstrieren die Ergebnisse dieser Arbeit, dass die ΔM500 Variante von SGLT3, welcher in ADHS-relevanten Hirnarealen exprimiert wird, dessen sub-stratinduzierte Natriumleitfähigkeit aufhebt und den Membraneinbau beeinträchtigen könnte, was in Wechselwirkung mit anderen genetischen ADHS Risikovarianten das Risiko für ADHS in Mutationsträgern beeinflussen kann.